Iron(Ii) Sulphate (1:1), Heptahydrate
Restless Legs Syndrome
Mayo ClinicSmall moleculePhase 4 / ApprovedDormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Restless Legs Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ropinirole GlaxoSmithKline | Phase 4 | A |
Ferric Cation University of Zurich | Phase 4 | BBB |
PRAMIPEXOLE Massachusetts General Hospital | Phase 4 | BB |
VITAMIN D University of Sao Paulo General Hospital | Phase 4 | BB |
Ferumoxytol Auerbach Hematology Oncology Associates P C | Phase 2 | B |
Marcaine Injectable Product Lowcountry Infectious Diseases | N/A | D |
Lidocaine Lowcountry Infectious Diseases | N/A | D |
Gabapentin GlaxoSmithKline | Unknown | D |
Same molecule, other indications
Iron(Ii) Sulphate (1:1), Heptahydrate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →